Merrimack Pharmaceuticals Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy

[at noodls] – CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study is … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view